

**AMENDMENTS**

Please cancel claims 8-10, 15, and 26-38.

1-38. Canceled.

Please add the following new claims.

39. (New) A method of extending corneal graft survival following corneal transplantation in a patient, comprising administering to said patient an effective amount of a pharmaceutical composition comprising an indolinone vascular endothelial growth factor receptor-3 (VEGFR-3) kinase inhibitor, whereby lymphangiogenesis is suppressed in the cornea of said patient.

40. (New) The method of claim 39, wherein said VEGFR-3 kinase inhibitor binds the VEGFR-3 catalytic domain.

41. (New) The method of claim 39, wherein said indolinone is selected from 3(2,4-dihydroxy-benzylidene)-1,3-dihydro-indol-2-one; 3-(3-fluoro-4-methoxy-benzylidene)-1,3-dihydro-indol-2-one; and 3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one.

42. (New) The method of claim 41, where said indolinone is 3(2,4-dihydroxy-benzylidene)-1,3-dihydro-indol-2-one.

43. (New) The method of claim 41, where said indolinone is 3-(3-fluoro-4-methoxy-benzylidene)-1,3-dihydro-indol-2-one.

44. (New) The method of claim 41, where said indolinone is 3-(4-dimethylamino-naphthalen-1-ylmethylene) -1,3-dihydro-indol-2-one.

45. (New) The method of claim 39, further comprising administering to said patient an anti-angiogenic agent.

46. (New) The method of claim 39 or claim 45, further comprising administering to said patient an immunosuppressive agent.

47. (New) The method of claim 39, wherein said pharmaceutical composition is administered prior to corneal transplantation.

48. (New) The method of claim 39, wherein said pharmaceutical composition is administered subsequent to corneal transplantation.

49. (New) The method of claim 39, comprising administering to said patient an effective amount of a pharmaceutical composition comprising a VEGFR-3 kinase inhibitor two or more times.

50. (New) The method of claim 49, comprising repeated administration over a period of at least one month.

51. (New) The method of claim 49, comprising repeated administration over a period of at least six months.

52. (New) The method of claim 49, comprising:

(a) administering to said patient prior to corneal transplantation a pharmaceutical composition comprising a VEGFR-3 kinase inhibitor; and

(b) administering to said patient subsequent to corneal transplantation a pharmaceutical composition comprising a VEGFR-3 kinase inhibitor,

whereby lymphangiogenesis is suppressed in the cornea of said patient.

53. (New) The method of claim 39, comprising systemic administration of said pharmaceutical composition.

54. (New) The method of claim 39, comprising local administration of said pharmaceutical composition.

55. (New) The method of claim 54, comprising topical administration of said pharmaceutical composition.

56. (New) The method of claim 54, comprising local injection of said pharmaceutical composition.

57. (New) The method of claim 54, said pharmaceutical composition released from an intraocular or periocular implant.